EP Patent

EP4237404A1 — Novel compounds

Assigned to Sitryx Therapeutics Ltd · Expires 2023-09-06 · 3y expired

What this patent protects

The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein A, L, RA1, RA2, RC and RD are as defined herein.

USPTO Abstract

The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein A, L, RA1, RA2, RC and RD are as defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP4237404A1
Jurisdiction
EP
Classification
—
Expires
2023-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Sitryx Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.